Paget's disease of bone (PDB) is a common disorder characterized by focal abnormalities of bone remodeling. We previously identified variants at the CSF1, OPTN and TNFRSF11A loci as risk factors for PDB by genome-wide association study 1 . Here we extended this study, identified three new loci and confirmed their association with PDB in 2,215 affected individuals (cases) and 4,370 controls from seven independent populations. The new associations were with rs5742915 within PML on 15q24 (odds ratio (OR) = 1.34, P = 1.6 × 10 −14 ), rs10498635 within RIN3 on 14q32 (OR = 1.44, P = 2.55 × 10 −11 ) and rs4294134 within NUP205 on 7q33 (OR = 1.45, P = 8.45 × 10 −10 ). Our data also confirmed the association of TM7SF4 (rs2458413, OR = 1.40, P = 7.38 × 10 −17 ) with PDB. These seven loci explained ~13% of the familial risk of PDB. These studies provide new insights into the genetic architecture and pathophysiology of PDB.
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PDB is a common skeletal disorder with a strong genetic component that affects up to 2% of individuals of European ancestry aged 55 years and above 2, 3 . Mutations of SQSTM1 are known to cause a highpenetrance form of PDB which is clinically severe 4 and occurs in about 40% of individuals with a family history of the disorder 5, 6 . We recently identified additional susceptibility alleles for PDB at the CSF1, OPTN and TNFRSF11A loci by a genome-wide association study (GWAS) involving 692 cases with PDB and 1,001 controls and a replication cohort of 481 cases and 520 controls 1 . In order to identify additional susceptibility loci for the disease, we performed an extended GWAS involving a total of 749 cases with PDB of British descent in whom SQSTM1 mutations had been excluded and 2,930 British controls derived from the 1958 Birth Cohort 7 with replication in a further 1,474 cases and 1,671 controls from six independent populations.
After applying quality control measures and excluding samples of non-European ancestry, the extended cohort (henceforth referred to as the GWAS stage) comprised 741 cases and 2,699 controls with genotype information for 290,115 SNPs, providing a fourfold increase in power to detect loci of moderate effect size (OR ≥ 1.4) compared with our previous study 1 . To increase SNP coverage, we performed genome-wide SNP imputation for the GWAS stage samples using phased haplotype data from the HapMap project as a reference. The results of the association testing of genotyped and imputed SNPs (a total of 2,487,078 SNPs) from the GWAS stage are shown in Figure 1 . A locus on chromosome 8q22.3 showed genome-wide evidence of association with PDB (P < 5.0 × 10 −8 ), in addition to the previously identified genome-wide significant loci on 1p13.3, 10p13 and 18q21. 33 (ref. 1) .
In the second stage of this study, we analyzed the highest ranking SNPs observed in the GWAS stage (P ≤ 5 × 10 −5 ) for replication after excluding those in linkage disequilibrium (LD; r 2 > 0.8 or l e t t e r s D′ > 0.95) with the highest ranking SNP from each region. We genotyped a total of 27 SNPs in the replication cohorts, which consisted of 1,474 SQSTM1-negative cases with PDB from six different geographic regions and 1,671 unaffected controls from the same regions that were matched with the cases by gender, as described in the Online Methods section and Supplementary Table 1 . We performed a meta-analysis of data from the GWAS stage and the individual replication cohorts, and the results are summarized in Supplementary Table 2 . This strengthened the association with PDB for the CSF1, OPTN and TNFRSF11A loci that we identified in our previous study 1 and confirmed the association with the 8q22.3 locus that was suggestively associated with PDB in our previous GWAS 1 and which was confirmed to be associated with PDB in a small study of Belgian and Dutch subjects 8 . Furthermore, we identified three additional genome-wide significant loci on 7q33, 14q32.12 and 15q24.1 in the combined dataset (P < 5 × 10 −8 ; Table 1 and Fig. 2) .
The strongest signal on 8q22.3 was with rs2458413 (combined P = 7.38 × 10 −17 , OR = 1.4). There was no significant heterogeneity between the study groups ( Table 1, Fig. 3 and Supplementary Table 3) , and the direction of association was similar in all cohorts. The associated region spans ~220 kb, but the SNPs with the highest association signal appear to cluster within an 18-kb LD block spanning the entirety of TM7SF4, the transmembrane 7 superfamily member 4 gene ( Fig. 2 and Supplementary Fig. 1 ). This gene encodes the dendritic-cell-specific transmembrane protein (DC-STAMP) 9 , which is a strong functional candidate gene for PDB because it is required for the fusion of osteoclast precursors to form mature osteoclasts 10 . Previous studies have shown that RANKL-induced DC-STAMP expression is essential for osteoclast formation 11 , and a recent study showed that the connective tissue growth factor CCN2 stimulates osteoclast fusion through interaction with DC-STAMP 12 . Because osteoclasts from individuals with PDB are larger in size and contain more nuclei than normal osteoclasts, it seems likely that the genetic variants that predispose to PDB do so by enhancing TM7SF4 expression or by causing gain of function at the protein level, but further studies will be required to investigate these possibilities.
The first new locus for PDB susceptibility was on 7q33, which is tagged by rs4294134 (combined P = 8.45 × 10 −10 , OR = 1.45). The direction of association was similar in all study cohorts, and analysis of the combined dataset showed no evidence for heterogeneity between study groups (Table 1, Fig. 3 and Supplementary Table 3 ). The associated region spans ~350 kb (Fig. 2) , but the strongest signal was with rs4294134, located within the twenty-second intron of NUP205. This gene encodes nucleoporin 205 kDa, which is one of the main components of the nuclear pore complex involved in the regulation of transport between the cytoplasm and nucleus 13 . All SNPs with P < 1 × 10 −5 in the 350-kb associated region were in moderate to strong LD with rs4294134 (r 2 ≥ 0.5, D′ ≥ 0.95), with the exception of two SNPs (rs3110788 and rs3110794) that were poorly correlated with rs4294134 (r 2 ≤ 0.21, D′ ≥ 0.95; Fig. 2 ). Conditional analysis in the GWAS stage indicated that the association signal appeared to be driven by rs4294134 (P = 8.8 × 10 −3 ) after adjusting for rs3110788 (P = 0.31) and rs3110794 (P = 0.10). None of the genes located in this region are known to affect bone metabolism, and further studies will be required to identify the functional variant(s) responsible for association with PDB.
The second new susceptibility locus was located on 14q32.12 and was tagged by rs10498635. This SNP showed borderline evidence of association with PDB in our previous study (P = 9.69 × 10 −8 ) 1 but reached genome-wide significance in the present study (combined P = 2.55 × 10 −11 , OR = 1.44). Association testing showed no evidence for heterogeneity between the study groups ( Table 1, Fig. 3 and Supplementary Table 3 ). The 62-kb associated region is bounded by two recombination hotspots and contains RIN3 (Fig. 2) , which encodes the Ras and Rab interactor 3, a protein that plays a role in vesicular trafficking through showed significant heterogeneity but random-effect results were genome-wide significant (P = 4.34 × 10 −12 , OR = 1.68).
l e t t e r s interaction with small GTPases such as Ras and Rab 14, 15 . The function of RIN3 in bone metabolism is currently unknown, but it could play a role in bone resorption in view of the importance that small GTPases play in vesicular trafficking and in osteoclast function 16, 17 .
It is of interest to note that mutations affecting VCP, a protein also involved in vesicular trafficking, cause the syndrome of inclusion body myopathy with early onset Paget's disease and frontotemporal dementia 18 . The third new susceptibility locus was located on 15q24.1, and the strongest association was with rs5742915 (combined P = 1.60 × 10 −14 ; OR = 1.34; Table 1 , Fig. 3 and Supplementary Table 3) . The associated region is bounded by two recombination hotspots and spans ~200 kb, but we observed a gap spanning ~40 kb in this region with no SNP coverage in the Illumina arrays or the HapMap European CEU population. The associated SNPs were clustered within PML, the promyelocytic leukemia gene (Fig. 2) , and we observed the strongest signal for rs5742915, which results in a phenylalanine to leucine amino acid change at codon 645 (p.Phe645Leu) of PML. The function of PML in bone metabolism is unclear, but it is known to be involved in TGF-β signaling 19 . Accordingly, researchers from a previous study showed that cells from Pml knockout mice were resistant to TGF-β-dependent growth arrest and apoptosis and had impaired induction of TGF-β target genes 19 . Because TGF-β is known to play a role in the regulation of bone remodeling, it is possible that the association between PDB and PML could be mediated by an effect on TGF-β signaling, but further research will be required to investigate this possibility. GOLGA6A is also located in the associated region and encodes a protein that belongs to golgin, a family of coiled-coil proteins associated with the Golgi apparatus and which play a role in membrane fusion and as structural supports for the Golgi cisternae. This gene is located in the 40-kb gap region that contains a large low-copy repeat sequence. Although GOLGA6A has no known role in bone metabolism, mutations in other members of the golgin family have been shown to cause lethal skeletal dysplasia 20 Figure 3 Forest plots showing association in the different datasets for SNPs at 7q33, 8q22.3, 14q32.12 and 15q24.1. (a-d) Forest plots of overall effect size for SNPs associated with PDB risk from the identified loci on 7q33 (rs4294134) (a), 8q22.3 (rs2458413) (b), 14q32.12 (rs10498635) (c) and 15q24.1 (rs5742915) (d). We estimated the overall effect size using meta-analysis of the GWAS sample and the six replication samples. The black squares represent the effect estimates for the individual cohorts, and the horizontal lines represent the 95% CIs of the estimates. The sizes of the squares are proportionate to the weights of the estimates. The diamonds and triangles represent the overall estimate under fixed-effect and random-effect models, respectively. The dotted vertical lines represent the overall fixed effect estimates.
l e t t e r s
We were also able to replicate our previously reported association between variants at the CSF1, OPTN and TNFRSF11A loci and PDB in the present study 1 . The results of our meta-analysis of the combined dataset for these loci are shown in Table 1 and Supplementary Figure 2 , which provide conclusive evidence for association of variants at CSF1 (P = 7.06 × 10 −35 ), OPTN (P = 4.37 × 10 −38 ) and TNFRSF11A (P = 7.98 × 10 −21 ) with PDB. We observed evidence of heterogeneity between the study groups for rs1561570 (I 2 = 65.7%, P het = 0.01) at OPTN, but this was because of differences in effect size rather than the direction of effect, and the association remained genome-wide significant after accounting for heterogeneity (P = 4.34 × 10 −12 , OR = 1.68). The heterogeneity was caused by the larger effect size observed in the Dutch cohort (Supplementary Fig. 2 ) and possibly because of the small sample size of this cohort. These observations provide highly robust evidence for association between these loci and PDB and extend those recently reported 8 in the Dutch and Belgian populations, which were also included in the present study.
We next wanted to determine if the identified loci on 15q24.1, 7q33 and 14q32.12 interacted with each other or with the previously identified loci on 1p13.3, 8q22.3, 10p13 and 18q21.33 to affect the risk of PDB. Pairwise interaction analysis showed weak evidence for interaction of 7q33 (rs4294134) with 8q22.3 (rs2458413, P = 0.03) and 10p13 (rs1561570, P = 0.02). However, these interactions were not significant after adjusting for multiple testing, and none of the other loci showed evidence for interaction (P > 0.05), suggesting a multiplicative model of association with PDB risk. In order to estimate the effect size of the identified loci on the development of PDB, we calculated the proportion of familial risk explained by the genomewide significant loci in the replication sample assuming a sibling relative risk for PDB of 7.0 (ref. 22) . This showed that the proportion of familial risk explained was ~13%, which is much greater than that observed for other common bone diseases, such as osteoporosis 23 . We also estimated the cumulative population attributable risk of these loci in the replication cohort and found it to be 86%, and we found that the risk of PDB increased with the increasing number of risk allele scores defined by the seven loci (per risk allele OR = 1.44, 95% CI 1.38-1.51, P = 5.4 × 10 −57 ). When we weighted allele scores according to their estimated effect size, we found that subjects in the top 10% of the allele score distribution (D10; n = 315) had a 10.1-fold (95% CI 7.0-14.6, P = 2.4 × 10 −39 ) increase in risk of developing PDB compared to those in the bottom 10% of the distribution (D1; n = 315) from the replication dataset (Fig. 4) . Although these data suggest that a large part of the genetic risk of PDB in individuals without SQSTM1 mutations is accounted for by these loci, we acknowledge that the functional variants need to be identified before we can precisely estimate the contribution that these loci make to the risk of developing PDB. To assess the functional effect of the identified SNPs on gene expression, we tested the association between the top PDB-associated SNPs (or those in LD with these SNPs; D′ ≥ 0.8) from each of the seven loci and cis-allelic expression of genes located in the associated regions using publicly available expression quantitative trait loci (eQTL) data. This showed highly significant associations for transcripts of TM7SF4 (rs2458415, expression P = 1.22 × 10 -18 ) and OPTN (rs1561570, expression P = 6.61 × 10 -62 ) in peripheral blood monocytes 24 , suggesting that the association with PDB risk for these loci could be mediated by influencing gene expression levels.
In addition to the loci mentioned above, we identified additional variants that showed suggestive evidence for association with PDB. For example, a locus on chromosome Xq24 showed borderline evidence for association with PDB (rs5910578 within SLC25A43, combined P = 1.26 × 10 −7 , OR = 1.34), as did another locus on chromosome 6p22.3 (rs1341239 near PRL, combined P = 3.83 × 10 −6 , OR = 1.20; Supplementary Table 2 ). Given that we observed six genotyped variants with P < 1 × 10 −5 in the GWAS stage after removal of confirmed SNPs and associated variants when only three are expected by chance (Supplementary Fig. 3) , it is likely that some of the associations observed are true, but our study was not sufficiently powered to detect them at a genome-wide significant level.
This study has been successful in identifying seven loci that contribute substantially to the risk of developing PDB. The identified loci have relatively large effect sizes compared to other common diseases of the musculoskeletal system such as osteoporosis and rheumatoid arthritis. This indicates that susceptibility to PDB is probably mediated by inheritance of a relatively small number of genes with large effect sizes as opposed to a large number of genes with small effect sizes, as seen in other complex diseases. Many of the susceptibility variants are within or close to genes that are known to play important roles in regulating osteoclast differentiation and function, whereas other variants are within genes not previously implicated in the regulation of bone metabolism. Although further work will be required to identify functional variants, the present study has provided new insights into the genetic architecture of PDB and has identified several genes that were not previously suspected to play a role in bone metabolism. Finally, the large effect size of the variants identified means that it may be possible in the future to identify people at risk of developing PDB by genetic profiling.
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Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturegenetics/. Figure 4 Cumulative contribution of genome-wide significant loci to the risk of PDB. Risk allele scores defined by the seven loci associated with PDB risk are plotted against the OR for PDB. We weighted risk alleles according to their estimated effect size and divided weighted risk allele scores into ten equal parts (deciles) using data from the replication cohorts. We calculated the OR for PDB risk for each decile in reference to the fifth decile (D5). Vertical bars represent 95% CIs.
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